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Abstract
Background: UNAIDS calls for fewer than 500,000 new HIV infections/year by 2020, with treatment-as-prevention
being a key part of their strategy for achieving the target. A better understanding of the contribution to
transmission of people at different stages of the care pathway can help focus intervention services at populations
where they may have the greatest effect. We investigate this using Uganda as a case study.
Methods: An individual-based HIV/ART model was fitted using history matching. 100 model fits were generated to
account for uncertainties in sexual behaviour, HIV epidemiology, and ART coverage up to 2015 in Uganda. A
number of different ART scale-up intervention scenarios were simulated between 2016 and 2030. The incidence
and proportion of transmission over time from people with primary infection, post-primary ART-naïve infection, and
people currently or previously on ART was calculated.
Results: In all scenarios, the proportion of transmission by ART-naïve people decreases, from 70% (61%–79%) in
2015 to between 23% (15%–40%) and 47% (35%–61%) in 2030. The proportion of transmission by people on ART
increases from 7.8% (3.5%–13%) to between 14% (7.0%–24%) and 38% (21%–55%). The proportion of transmission
by ART dropouts increases from 22% (15%–33%) to between 31% (23%–43%) and 56% (43%–70%).
Conclusions: People who are currently or previously on ART are likely to play an increasingly large role in
transmission as ART coverage increases in Uganda. Improving retention on ART, and ensuring that people on ART
remain virally suppressed, will be key in reducing HIV incidence in Uganda.
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Background
The Joint United Nations Programme on HIV/AIDS
(UNAIDS) ‘fast-track targets’ call for fewer than 500,000
new infections in adults per year by 2020 [1], down from
an estimated 2.1 million in 2015 [2]. 65% of new infec-
tions in 2015 occurred in sub-Saharan Africa, and
83,000 of these new infections occurred in Uganda, with
only South Africa, Nigeria, and India having larger num-
bers [2]. Uganda had an adult (15–49 years) prevalence
of HIV of 7.3% at the time of the last national prevalence
survey in 2011, with an estimated 39% of HIV-infected
adults receiving ART in 2013 [3].
We currently have a limited understanding of who is
transmitting HIV, and how this varies by setting. A range
of studies have attempted to estimate the proportion of
transmission that occurs during primary infection, but a
large amount of uncertainty remains [4], and it is likely
that the proportion varies between different settings. We
have even less understanding of the contribution to
overall transmission of people at different stages of the
anti-retroviral therapy (ART) care pathway, and how this
will change as treatment coverage increases [5, 6]. While
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ART greatly reduces transmission risk [7], transmission
has been observed to occur from people receiving ART,
albeit at a low rate, and it is plausible that the rate of
transmission will be higher among people not part of re-
search cohorts [7]. An intriguing molecular study con-
ducted in Switzerland [8] suggests that, in that setting,
nearly half of transmission by people with post-primary
infections may occur after they have first initiated ART,
with much occurring during treatment interruptions.
The approach used in the study can only give very rough
estimates however, due to the difficulties in determining
the exact date of transmission. In addition, it can only
be used in countries that have routine viral sequencing.
Treatment-as-prevention is a key component of the
UNAIDS strategy to reduce HIV incidence. To meet the
ambitious goals of the strategy, it is necessary to develop
a better understanding of the relative contribution to
overall HIV transmission of people at different stages of
the care pathway. This will assist policy makers to focus
intervention services at populations where they are likely
to have the greatest effect. We investigate this using a
mathematical model of HIV transmission and ART
scale-up, using Uganda as a case study.
Methods
Model structure
A dynamic, individual-based model of HIV transmis-
sion and ART scale-up was developed in NetLogo [9].
The model simulates births, deaths, and population
growth; the formation and dissolution of sexual part-
nerships; HIV transmission; pre-ART care and first
and second line ART; and the development and
transmission of drug resistance. The model was de-
signed to accurately represent the key features of
major routes into and through pre-ART care and
ART in Uganda, as well as attrition and re-entry at
different stages. A full description of the model struc-
ture is given in McCreesh et al. [10].
Data, model parameterisation and fitting
The model was fitted to data on the estimated adult
(15–49 year-old) male and female population size in
Uganda in 2015, and the growth in population between
1950 and 2015. As no detailed, representative data on
sexual behaviour were available from Uganda as a whole,
the model was fitted to data on sexual behaviour from a
rural open general population cohort in South-West
Uganda [11–13]. This included data on the prevalence
and incidence of sexual partnerships, and the prevalence
of partnership concurrency. Two sexual behaviour risk
groups (high and low partnership incidence) and two
concurrency groups (high and low concurrency) were
simulated. All partnerships in the model had the same
duration.
The model was fitted to data from UNAIDS surveys
on the overall HIV prevalence in adults in Uganda in
1991, and the male and female adult HIV prevalences
in 2004 and 2011 [3]. Twenty-seven fitted outputs
were used to ensure that the model accurately repre-
sented HIV care and ART scale-up in Uganda. These
included, in a number of different years, the propor-
tion of men and women ever tested for HIV, the pro-
portion of HIV positive people on ART, the proportion of
people in HIV care on ART, the proportion of people
starting ART with a CD4 count <250 cells/μl (cut-off
chosen based on empirical data availability), the propor-
tion of people starting ART who were women, and the
proportion of people on second line ART. In addition, the
model was fitted to data on rates of dropping out of and
restarting ART in men and women, and 12-month reten-
tion on ART.
Six parameters controlled HIV transmission probabil-
ities in the model, with an additional parameter deter-
mining the mean duration of primary infection. One
parameter, baseline_transmission, determined the mean
per sex act transmission probability for a person with a
CD4 count between 200 and 350 cells/μl (unweighted
average of male to female and female to male transmis-
sion probabilities). All other transmission probabilities in
the model were calculated relative to this. No limits
were placed on the value of baseline_transmission, to
allow the model to be simultaneously fitted to the sexual
behaviour and HIV prevalence data. A second parameter
controlled the ratio of male to female and female to
male transmission probabilities. The plausible range for
this parameter was set to 1.1–4.8, in line with empirical
data [14]. As viral loads are correlated with CD4 counts,
transmission probabilities are likely to be lower at higher
CD4 counts (for post-primary infections), and higher at
lower CD4 counts. The plausible range for relative trans-
mission probabilites for people with CD4 counts <200
cells/μl and ≥350 cells/μl were considered to be 1.5–6.7
and 0.42–0.95 respectively [7]. Transmission probabil-
ities may be much higher for people with primary infec-
tions. A two-dimensional joint plausible range was
placed on input parameters determining the mean dur-
ation of primary infection, and the relative transmission
probability during primary infection, based on analysis
of empirical data by Bellan et al. [15].
Transmission probabilities for people on established
ART in the model varied according to their level of
drug resistance to the regimen that they were receiv-
ing (first or second line ART). With the maximum
number of active drugs, the plausible range for rela-
tive transmission probabilities was assumed to be
0.04–0.21 [16]. With no active drugs, the probability
of transmission was assumed to be the same as it
would be if they were not on ART. With intermediate
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numbers of active drugs, transmission probabilities in-
creased exponentially as the number of active drugs
declined.
The model was fitted to the empirical data using
history matching with model emulation, a calibration
method for complex models which iteratively removes
areas of the input space where fits to the data are un-
likely to be found [17, 18]. Overall, 96 input parame-
ters were varied during the fitting process, and the
model was fitted to 51 outputs. A total of 100 model
fits, all consistent with empirical data, were generated
using history matching. This approach allowed us to
comprehensively incorporate a large number of the
potential sources of uncertainty in our results, allow-
ing realistic estimates of uncertainty in model results
to be obtained. Full details are given in McCreesh et
al. [10].
Scenarios
A total of nine ART scale-up scenarios were simulated
from 2016, making different assumptions about how
ART will be scaled-up in Uganda:
1) Baseline. No changes to ART policy or
implementation after 2014.
2) Increased HIV testing. The rate of HIV testing was
doubled.
3) No CD4 threshold. The CD4 threshold for ART
initiation was removed.
4) Improved retention on ART. The rate of dropping
out of ART was halved.
5) Increased ART restart rates. The rate of restarting
ART after dropping out was doubled.
6) Improved pre-ART care. The rate of dropping out of
pre-ART care was halved, the probability of linking
to care following a positive HIV test was doubled,
and the rate of starting ART from pre-ART (when
eligible) was doubled.
7) Improved linkage to care. The probability of
linking to care following a positive HIV test was
doubled.
8) Universal test and treat (UTT). Combines increased
HIV testing rates, no CD4 threshold, and improved
linkage to care.
9) Universal test, treat and keep (UTTK). Combines
increased HIV testing rates, no CD4 threshold,
improved linkage to care, improved retention on
ART, and increased ART restart rates.
All changes were implemented from 2016, and all sce-
narios were run until 2030. A total of 100 model fits
were used in the analysis. Results were averaged over
2000 (stochastic) repetitions for each scenario and model
fit.
Results
Fit to data
The model fitted closely to the acceptable ranges
from the empirical data for all 51 outputs. Figure 1
shows model fits in a range of years to HIV preva-
lence, ART coverage, the proportion of people starting
ART with CD4 < 250 cells/μl, and the proportion of
people starting ART who are female; male partnership
incidence in 2015; male and female ART dropout and
restart rates; and 12-month retention on ART. Model
fits to an additional 28 outputs are given in McCreesh et
al. [10].
Reductions in transmission input parameter ranges
The histograms in Fig. 2 show the distribution of values
in the 100 fitted runs for the seven input parameters that
control transmission. The red lines show the initial
plausible ranges, before model fitting. The ranges of five
of the seven transmission input parameters were not re-
duced during model fitting. In other words, fits were
found throughout the whole of the plausible range. The
two exceptions were baseline_transmission and the ratio
of male → female to female → male transmission prob-
abilities, where model fits were limited to within the
ranges 0.00083–0.0023 (initial plausible range 0–1) and
1.1–2.7 (initial plausible range 1.1–4.8) respectively.
The scatter graphs in Fig. 2 show the joint distribu-
tion of pairs of input parameters. While the distribu-
tion of most pairs was uncorrelated, there were
negative correlations in the final fitted runs between
baseline_transmission and the increase in transmission
probabilities in people with CD4 counts <250 cells/μl
(r = −0.63), and between baseline_transmission and
the decrease in transmission probabilities in people
with CD4 counts >350 cells/μl (r = −0.44).
HIV prevalence and ART coverage
The projected HIV prevalence in 2030 in adults aged be-
tween 15 and 49 years ranged between 4.9% (median;
90% plausible range 3.9%–7.5%) in the baseline sce-
nario to 3.7% (3.0%–5.4%) in the universal test, treat,
and keep (UTTK) scenario (Fig. 3a). The projected
proportion of HIV positive people who were ART-
naïve in 2030 ranged from 26% (21%–32%) in the
baseline scenario to 7.6% (5.0%–12%) in the UTTK
scenario, with <6% of HIV positive people having pri-
mary stage infections in all scenarios and model fits
(Fig. 3b). ART coverage of all HIV positive people in
2030 ranged from 55% (51%–60%) in the baseline sce-
nario, up to 82% (76%–85%) in the UTTK scenario.
Finally, the proportion of HIV positive people who
had dropped out of ART ranged from 11% (9.1%–
13%) in the UTTK scenario to 24% (21%–27%) in the
universal test and treat (UTT) scenario.
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Figure 4 shows trends over time in population com-
position between 2005 and 2030 in the baseline, UTT,
and UTTK scenarios.
HIV incidence
The overall annual incidence of HIV infection in 2015 in
the model was 0.61% (90% plausible range: 0.47–0.83%)
(Fig. 3c). Incidence fell between 2015 and 2030, falling
to 0.39% (0.26–0.73%) in 2030 in the baseline scenario,
and 0.18% (0.10%–0.35%) in the UTTK scenario. In all
scenarios, the biggest reductions in incidence occurred
as a result of lower transmission from people with post-
primary, ART-naïve infections, with the annual inci-
dence of infection by this group falling from 0.37%
(0.025%–0.52%) in 2015 to 0.14% (0.079%–0.27%) in
2030 in the baseline scenario and 0.025% (0.0012%–
0.066%) in 2030 in the UTTK scenario (Fig. 3d). In all
scenarios, the incidence of infection caused by transmis-
sion from people with primary infections fell between
2015 and 2030, and the incidence of infection from
people on ART increased slightly. Finally, the incidence
of infection due to transmission by people who had
dropped out of ART fell in scenarios that included inter-
ventions to reduce loss to follow up (improved ART
retention, increased ART restart rates, and UTTK), and
increased in all other scenarios.
Proportion of HIV incidence
The proportion of new infections resulting from
transmission by people with primary infections was very
similar in 2015 and in all scenarios in 2030, with the me-
dian proportion of transmission ranging from 7.9%–8.6%
(Fig. 3e). There was a large amount of uncertainty in the
proportion of transmission by people with primary stage
infections, with a 90% plausible range of 1.5%–25%.
In 2015, ART-naïve people were responsible for the
majority of new infections (70%, 90% plausible range
61%–79%), with people on ART, and ART dropouts,
contributing 7.8% (3.5%–13%) and 22% (15%–33%) of
new infections respectively. In all scenarios, the propor-
tion of transmission by people with post-primary, ART-
naïve infections fell greatly between 2015 and 2030, and
the proportion of transmission by people on ART and
people who have dropped out of ART increased.
The relative importance of transmission by people
with post-primary ART-naïve infections, people on
ART, and people who had dropped out of ART in
2030 varied greatly between scenarios. People with
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full width of the band shows the range of the model output. Graphs g-i: Orange boxes show the empirical data and acceptable ranges. Green
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post-primary ART-naïve infections were responsible
for between 14% (UTT, 7.9%–23%) and 37% (improved
retention, 27%–48%) of new infections, people on ART
were responsible for between 14% (baseline, 7.0%–24%)
and 38% (UTTK, 21%–55%) of new infections, and ART
drop-outs were responsible for between 31% (improved
retention, 23%–43%) and 56% (UTT, 43%–70%) of new
infections.
Discussion
Model results suggest that, as ART coverage increases
in Uganda, people on ART and people who have
dropped out of ART will be responsible for an in-
creasingly large proportion of all HIV transmission. In
2015, we estimate that these two groups were respon-
sible for 7.8% (3.5%–13%) and 22% (15%–33%) of all
transmission occurring during heterosexual sex re-
spectively. With no change in ART policy or imple-
mentation, this may increase to 14% (7.0%–24%) and
40% (29–51%) respectively by 2030. With a universal
test and treat (UTT) policy, the proportions may in-
crease to 20% (9.3%–32%) and 56% (43%–70%), and
with a (successfully implemented) universal test, treat,
and keep (UTTK) policy, the proportions may in-
crease to 38% (21–55%) and 35% (24%–53%).
Our findings have important implications for HIV
control. As ART coverage increases in Uganda and
elsewhere in sub-Saharan Africa, people who are cur-
rently or previously on ART are likely to play an in-
creasingly large role in overall HIV transmission. For
this reason, the focus of ‘treatment as prevention’ will
increasingly need to shift from finding treatment-
naïve HIV positive people and starting them on ART,
to also improving treatment adherence and retention
on ART, and ensuring that people are promptly
switched to 2nd line ART when necessary. Changes
in ART regimens and scale-up of viral load testing
may also have an important and increasing role in re-
ducing HIV transmission.
The relative contribution of different stages of the
ART care pathway to overall transmission will vary by
country, depending on details of the country’s ART
programme. In general, at higher ART coverages, a
higher proportion of transmission will be by people
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on ART. At the same ART coverage, the proportion
of transmission by ART drop-outs will be higher
when retention is lower. Estimated ART coverage of
all HIV+ adults in Uganda in 2015 was 57% [2]. This
is fairly typical for East and Southern Africa, where
overall coverage is estimated to be 54%. Estimated
coverage varies greatly by country however, ranging
from 29% in Angola to 78% in Botswana, and overall
coverage is lower in West and Central Africa, at 28%.
Representative data on ART retention in sub-Saharan
African countries is sparser; however, estimates avail-
able from East and Southern Africa range from 66%
retention at 12 months in Mozambique, to 93% in
Zambia. In Uganda, 12-month retention in 2015 was
estimated to be 78%. The proportion of transmission
by people on ART and ART drop-outs will therefore
vary by country. Nevertheless, these groups are likely
to be responsible for an increasing proportion of
transmission as ART programmes are scaled-up
across sub-Saharan Africa.
In our model, being on ART (with no resistance to
the drug regimen) reduced HIV transmission prob-
abilities by 79–96%. This plausible range was equal to
the 95% confidence interval from an empirical study
of transmission in discordant couples in sub-Saharan
Africa [7]. The point estimate from this study was a
92% reduction in transmission probabilities. A second
study estimated that ART reduced transmission prob-
abilities by 96% (95% CI: 73–99%) [19]. These reduc-
tions are slightly higher than the mean reduction of
88% in our 100 model runs. Adherence is likely to be
higher in research study cohorts than in the general
population however [20], and therefore our lower
simulated mean reduction may be more realistic for
Uganda as a whole.
A number of mathematical modelling studies have
estimated the proportion of transmission that occurs
during primary infection in a wide range of different
populations and settings, with estimates ranging from
<1% to 93% [4, 21]. Our median estimate of 8.1% of
transmission occurring during primary infection in
2015 is low compared to the majority of studies. This
is most likely because HIV incidence was declining in
2015 in our model, whereas most previous models
have simulated increasing or stable epidemics. All else
being equal, when incidence is falling, a lower pro-
portion of HIV positive people will have primary in-
fections, and they will therefore contribute less to
overall incidence. Our 90% plausible range was wide
(1.5% to 24%), reflecting the large amount of
Fig. 3 a) Overall HIV prevalence in 2015 and 2030 by intervention; b) Proportion of HIV+ people by stage; c) Overall HIV incidence in 2015 and
2030 by intervention; d) HIV incidence by stage in 2015 and by stage and intervention in 2030; e) Proportion of new infections due to
transmission by people in each stage in 2015 and by stage and intervention in 2030. Boxes show the median and 25–75% quartiles. Whiskers
show the highest/lowest value that is within 1.5 times the inter-quartile range from the 75%/25% quartile. Crosses show the 90% plausible range.
Results for 2015 are shown in black
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uncertainty that still exists in the duration and rela-
tive infectiousness of primary infection. It also dem-
onstrates the importance of fully incorporating levels
of uncertainty in input parameters into model projec-
tions, something that is often neglected in infectious
disease modelling.
Conclusions
People who are currently or previously on ART are likely
to play an increasingly large role in overall transmission
as ART coverage increases in Uganda and other sub-
Saharan African countries. Improving adherence and re-
tention on ART, and ensuring that people on ART are
on effective drug regimens, will be key in reducing the
overall incidence of HIV in Uganda. In other words,
achieving the 2nd and 3rd UNAIDS ‘90s’ (90% of all
people with diagnosed HIV infection receiving sustained
antiretroviral therapy by 2020, and 90% of all people
receiving ART achieving viral suppression) [22] is likely
to become increasingly important to reducing HIV
incidence.
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